ライフサイエンスコーパス: infusion pump

1 ivered with a Medtronic MiniMed subcutaneous infusion pump.

2 inuously administered for 2 weeks through an infusion pump.

3 tion or continuous infusion via an implanted infusion pump.

4 y mass (Intralipid(R) 20%) at 1 mL/min using infusion pumps.

5 us the invasiveness of implanted cannulae or infusion pumps(2).

6 ts underwent resection (60%), hepatic-artery infusion pumping (50%), and/or radiofrequency ablation (

7 PD received rhPDGF-BB via an implanted drug infusion pump and an investigational i.c.v. catheter.

8 ps for the surgical implantation of an ALZET infusion pump and the placement of its catheter.

9 ne to use stored syringes of propofol in the infusion pump and to reuse propofol syringes.

10 Treatment was given using an infusion pump and was repeated at 4- to 12-wk intervals

11 lete mathematical framework to optimize drug infusion pumps and inform on inter-patient PK variabilit

12 The availability of ambulatory infusion pumps and paclitaxel-compatible tubing permitte

13 Rats were implanted with chronic infusion pumps and received diluent or three doses of IL

14 reconstitution of the drug, operation of the infusion pump, and others) has led to attempts to develo

15 Life-saving equipment such as ventilators, infusion pumps, and monitors became useless.

16 Toward those ends, osmotic infusion pumps can be useful for overcoming limitations

17 Infusion of 5-HT into mice with miniosmotic infusion pumps caused activation of Smads 1/5/8 in lung

18 igate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with ove

19 Osmotic infusion pumps containing either diluent or TNF-alpha we

20 nic injection cannulae connected to an Alzet infusion pump filled with the GABA synthesis inhibitor L

21 EP was stable in infusion pumps for at least 7 days.

22 Hepatic arterial infusion pump (HAIP) chemotherapy has a potential surviv

23 Hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine aims

24 Continuous insulin infusion pumps have been widely available for over two d

25 al fluid drains, implantation of intrathecal infusion pumps, implantation of deep brain stimulation h

26 ia chronomodulated schedules delivered by an infusion pump into the hepatic artery were mathematicall

27 n, a model protein, utilizing a programmable infusion pump (iPRECIO SMP-310R) in a mouse model.

28 A high precision infusion pump is critical for maintaining constant flow

29 A programmable dual-syringe infusion pump is used to introduce a solution of time-va

30 venous prostacyclin administered by portable infusion pump on a compassionate-use basis.

31 determined either by removal of the osmotic infusion pumps on day 15 or by treatment of the animals

32 rtially reversible by removal of the osmotic infusion pumps or treatment of the animals with TNFR:Fc.

33 outpatient setting requires the use of basic infusion pumps, patient education and a mechanism for fo

34 d 70 laparotomy with biopsy only or arterial infusion pump placement ("chemotherapy only," 17%).

35 section during laparotomy for hepatic artery infusion pump placement.

36 t preservative, which was administered by an infusion pump (RR, 8.8; P = 0.048) were identified as ri

37 placed catheters and 19 through implantable infusion pumps (Shiley Infusaid Inc, Noorwood, MA).

38 able preprogrammed microprocessor-controlled infusion pump that delivers a gradually escalating dose

39 glucose and triggers insulin release from an infusion pump to enter the blood stream from a small res

40 visioned for use with transdermal patches or infusion pumps to achieve painless delivery of drugs to

41 istration of medications through intravenous infusion pumps to critically ill patients can result in

42 amic parameters to drive computer-controlled infusion pumps to deliver blood, lactated Ringer's solut

43 toposide levels (Css) and stability of EP in infusion pumps were measured using high performance liqu